SSTR2 and neuroendocrine neoplasm: Although SST2 is clearly the most prominent receptor expressed in gastroenteropancreatic neuroendocrine neoplasms, SST3 was also detected in 52%–90% of cases (Lupp et al., 2012; Kaemmerer et al., 2015b; Qian et al., 2016).